Annual Cash & Cash Equivalents
$80.34 M
+$28.12 M+53.86%
31 December 2023
Summary:
Foghorn Therapeutics annual cash & cash equivalents is currently $80.34 million, with the most recent change of +$28.12 million (+53.86%) on 31 December 2023. During the last 3 years, it has fallen by -$12.46 million (-13.43%). FHTX annual cash & cash equivalents is now -20.57% below its all-time high of $101.14 million, reached on 31 December 2021.FHTX Cash And Cash Equivalents Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Quarterly Cash And Cash Equivalents
$57.68 M
-$81.27 M-58.49%
30 September 2024
Summary:
Foghorn Therapeutics quarterly cash and cash equivalents is currently $57.68 million, with the most recent change of -$81.27 million (-58.49%) on 30 September 2024. Over the past year, it has dropped by -$12.63 million (-17.96%). FHTX quarterly cash and cash equivalents is now -73.00% below its all-time high of $213.65 million, reached on 31 March 2022.FHTX Quarterly Cash And Cash Equivalents Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
FHTX Cash And Cash Equivalents Performance
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly |
|---|---|---|
| 1 y1 year | +53.9% | -18.0% |
| 3 y3 years | -13.4% | -0.3% |
| 5 y5 years | +100.7% | - |
FHTX Cash And Cash Equivalents High & Low
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | |
|---|---|---|---|---|---|
| 3 y | 3 years | -20.6% | +53.9% | -73.0% | +13.9% |
| 5 y | 5 years | -20.6% | +436.3% | -73.0% | +285.0% |
| alltime | all time | -20.6% | +436.3% | -73.0% | +285.0% |
Foghorn Therapeutics Cash And Cash Equivalents History
| Date | Annual | Quarterly |
|---|---|---|
| Sept 2024 | - | $57.68 M(-58.5%) |
| June 2024 | - | $138.95 M(+75.3%) |
| Mar 2024 | - | $79.25 M(-1.3%) |
| Dec 2023 | $80.34 M(+53.9%) | $80.34 M(+14.3%) |
| Sept 2023 | - | $70.31 M(+21.8%) |
| June 2023 | - | $57.70 M(+13.9%) |
| Mar 2023 | - | $50.64 M(-3.0%) |
| Dec 2022 | $52.21 M | $52.21 M(-40.4%) |
| Sept 2022 | - | $87.60 M(+43.1%) |
| June 2022 | - | $61.21 M(-71.4%) |
| Date | Annual | Quarterly |
|---|---|---|
| Mar 2022 | - | $213.65 M(+111.2%) |
| Dec 2021 | $101.14 M(+9.0%) | $101.14 M(+74.9%) |
| Sept 2021 | - | $57.84 M(-53.8%) |
| June 2021 | - | $125.17 M(+88.4%) |
| Mar 2021 | - | $66.45 M(-28.4%) |
| Dec 2020 | $92.80 M(+519.4%) | $92.80 M(+24.4%) |
| Sept 2020 | - | $74.62 M(+104.1%) |
| June 2020 | - | $36.56 M(+144.1%) |
| Dec 2019 | $14.98 M(-62.6%) | $14.98 M |
| Dec 2018 | $40.02 M | - |
FAQ
- What is Foghorn Therapeutics annual cash & cash equivalents?
- What is the all time high annual cash & cash equivalents for Foghorn Therapeutics?
- What is Foghorn Therapeutics annual cash & cash equivalents year-on-year change?
- What is Foghorn Therapeutics quarterly cash and cash equivalents?
- What is the all time high quarterly cash and cash equivalents for Foghorn Therapeutics?
- What is Foghorn Therapeutics quarterly cash and cash equivalents year-on-year change?
What is Foghorn Therapeutics annual cash & cash equivalents?
The current annual cash & cash equivalents of FHTX is $80.34 M
What is the all time high annual cash & cash equivalents for Foghorn Therapeutics?
Foghorn Therapeutics all-time high annual cash & cash equivalents is $101.14 M
What is Foghorn Therapeutics annual cash & cash equivalents year-on-year change?
Over the past year, FHTX annual cash & cash equivalents has changed by +$28.12 M (+53.86%)
What is Foghorn Therapeutics quarterly cash and cash equivalents?
The current quarterly cash and cash equivalents of FHTX is $57.68 M
What is the all time high quarterly cash and cash equivalents for Foghorn Therapeutics?
Foghorn Therapeutics all-time high quarterly cash and cash equivalents is $213.65 M
What is Foghorn Therapeutics quarterly cash and cash equivalents year-on-year change?
Over the past year, FHTX quarterly cash and cash equivalents has changed by -$12.63 M (-17.96%)